All canine diagnoses

Your dog was diagnosed with Dermal / Subcutaneous Hemangiosarcoma. Dermal HSA (actinic / solar-induced) occurs in lightly pigmented, short-haired dogs on ventral abdomen and prepuce. Biologically less aggressive than visceral HSA. Subcutaneous HSA has intermediate behaviour — worse than dermal, better than splenic. Compare 2 treatment options for dogs including Wide Surgical Excision (Dermal HSA), Wide Excision + Adjuvant Doxorubicin (Subcutaneous HSA) — with survival times, costs, and what to expect during treatment.

🐕

Dermal / Subcutaneous Hemangiosarcoma

BreedsWhippetGreyhoundAmerican Pit Bull TerrierDalmatianBeagleItalian GreyhoundStaffordshire Bull Terrier
canine

Mesenchymal

About This Cancer

Hemangiosarcoma of the skin and tissues just beneath it has a notably different behaviour from the visceral (organ-based) forms of this cancer. Dermal hemangiosarcoma, found in the outermost layer of skin, is often caused by chronic sun exposure (ultraviolet radiation) and tends to occur on the thinly haired ventral abdomen of light-skinned dogs. This sun-induced form generally carries a better prognosis because it is caught earlier and is less likely to spread internally. Subcutaneous hemangiosarcoma, found in the fatty tissue beneath the skin, behaves more aggressively — intermediate between dermal and visceral forms. Short-haired, lightly pigmented breeds such as Whippets, Greyhounds, and Dalmatians are most at risk for the sun-induced variant.

Prognostic Factors(2)
Depth of invasionDermal (confined to dermis): MST ~780 days, rarely metastasises. Subcutaneous: MST months, ~60% recurrence. Intramuscular: MST ~273 days with treatment.
Actinic (solar) aetiologyUV-related dermal HSA has best prognosis — may survive years after excision. Not typically aggressive.(ABROVET consensus, 2023)
Minimum Workup(5 steps)
1Histopathology with depth assessment (dermal vs subcutaneous vs intramuscular)
2Complete blood count and biochemistry
3Three-view thoracic radiographs
4Abdominal ultrasound (rule out concurrent visceral HSA)
5Regional lymph node assessment

Median Survival Time Comparison

How long the average patient survives with each treatment

Bar opacity reflects evidence strength
Wide Surgical Excision (Dermal HSA)
~26 mo
Wide Excision + Adjuvant Doxorubicin (Subcutaneous HSA)
See notes
Reading this page: MST (Median Survival Time) is how long the average patient survives with a given treatment. ORR (Overall Response Rate) is the percentage of patients whose tumour shrank or disappeared. CR = Complete Response (tumour gone); PR = Partial Response (tumour shrank). Hover over any abbreviation for a quick explanation.
Strength of Evidence

Each treatment is rated by how much published research supports its use. Solid bars indicate stronger evidence; dashed bars mean less certainty.

StrongLarge published studies with strong agreement among veterinary oncologists.
ModerateWidely used in clinical practice, but supported by smaller or retrospective studies.
IndirectEvidence comes from a different tumour type or species and has been applied here.
LimitedVery little published data is available for this specific treatment.

Please note: All treatment data is sourced from published peer-reviewed literature. Survival times and cost figures are approximate guides. Your pet's individual factors — including tumour grade, stage, and overall health — will influence outcomes and should guide all treatment decisions. The strength-of-evidence rating reflects how much research exists, not how strongly a treatment is recommended. This tool is designed to help you have informed conversations with your veterinary oncologist, not to replace them. Costs shown are US referral centre estimates and may vary significantly by region.